IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Iovance Biotherapeutics raised full-year 2026 revenue guidance from $350–370M to $410–420M (midpoint +$55M, ~15% increase), driven by strong U.S. demand for Amtagvi (lifileucel) and Proleukin. The company reported record Q2 2026 product revenue of $99.3M and expanded its authorized treatment center network to ~100 centers with plans for ≥110 by year-end 2026; the raised guidance implies ~60% annual revenue growth.
Why this rating
Guidance raise of $55M midpoint is ~10% of company's $534.8M market cap; strong commercial execution and path to profitability are material. However, company remains pre-profitable and execution risk remains.
Price action (we called it positive)
before filing · preread $11.56 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.